Post-NET KI-67 index is a valuable prognostic biomarker in women with HR+/HER2- early breast cancer

Is the KI-67 level after neoadjuvant endocrine therapy associated with disease recurrence and survival in women with HR+ / HER2- early breast cancer? That question was the subject of a systematic review and meta-analysis performed by a research team of the Jules Bordet Institute in Brussels.

Dr. Diogo Martins-Branco explains the methodology, the results and the main conclusions of their analysis.